We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-9.41%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$982M
AUM Growth
+$21.4M
Cap. Flow
+$184M
Cap. Flow %
18.72%
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$29.1M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$19.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.4M
5
TDOC icon
Teladoc Health
TDOC
+$12.2M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$24.5M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$14.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.44M
4
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M
5
BLUE
bluebird bio
BLUE
+$3.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.92%
2 Technology 1.53%
3 Real Estate 0.71%
4 Communication Services 0.66%
5 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
26
Vanda Pharmaceuticals
VNDA
$302M
$12.2M 1.24%
2,153,307
+401,653
+23% +$2.07M
OTLK icon
27
Outlook Therapeutics
OTLK
$191M
$12M 1.22%
1,619,412
– –
AZN icon
28
AstraZeneca
AZN
$250B
$11.7M 1.19%
75,000
– –
KNSA icon
29
Kiniksa Pharmaceuticals
KNSA
$5.93B
$11.7M 1.19%
625,309
+125,309
+25% +$2.35M
NUVB icon
30
Nuvation Bio
NUVB
$2.32B
$11M 1.12%
3,751,864
+200,000
+6% +$610K
APLT
31
DELISTED
Applied Therapeutics
APLT
$10.9M 1.11%
2,330,000
+100,000
+4% +$473K
ACET icon
32
Adicet Bio
ACET
$74.7M
$9.94M 1.01%
513,560
+113,097
+28% +$3.03M
TDOC icon
33
Teladoc Health
TDOC
$1.3B
$9.78M 1%
+1,000,000
New +$12.2M
CTMX icon
34
CytomX Therapeutics
CTMX
$754M
$9.51M 0.97%
7,791,936
+1,341,936
+21% +$2.67M
CRGX
35
DELISTED
CARGO Therapeutics
CRGX
$9.4M 0.96%
572,697
+105,888
+23% +$2.01M
ZYME icon
36
Zymeworks
ZYME
$1.67B
$9.36M 0.95%
1,100,000
– –
IMNM icon
37
Immunome
IMNM
$2.83B
$8.71M 0.89%
720,000
– –
HRMY icon
38
Harmony Biosciences
HRMY
$2.24B
$8.48M 0.86%
281,200
– –
ELEV
39
DELISTED
Elevation Oncology
ELEV
$8.26M 0.84%
3,060,000
– –
BIIB icon
40
Biogen
BIIB
$30.7B
$8.11M 0.83%
+35,000
New +$7.61M
BDTX icon
41
Black Diamond Therapeutics
BDTX
$112M
$7.47M 0.76%
1,603,200
– –
REPL icon
42
Replimune Group
REPL
$1.01B
$7.25M 0.74%
+805,440
New +$5.61M
VTYX
43
DELISTED
Ventyx Biosciences
VTYX
$7.16M 0.73%
3,100,000
– –
IONS icon
44
Ionis Pharmaceuticals
IONS
$9.4B
$7.15M 0.73%
150,000
– –
DNTH icon
45
Dianthus Therapeutics
DNTH
$6.09B
$6.85M 0.7%
264,692
– –
INSM icon
46
Insmed
INSM
$28.6B
$6.7M 0.68%
+100,000
New +$3.88M
HRTX icon
47
Heron Therapeutics
HRTX
$92.9M
$6.47M 0.66%
1,850,000
– –
VKTX icon
48
Viking Therapeutics
VKTX
$4B
$6.36M 0.65%
120,000
+20,000
+20% +$1.31M
BEAM icon
49
Beam Therapeutics
BEAM
$2.84B
$6.33M 0.64%
+270,000
New +$6.63M
DTIL icon
50
Precision BioSciences
DTIL
$207M
$6.07M 0.62%
623,332
+33,763
+6% +$398K
1
2
3 4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Tang Capital Management held 143 positions worth $982M, up 2.2% from $960M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tang Capital Management deployed $184M of net new capital in Q2 2024, opening 43 new positions and adding to 40 existing holdings. Its largest new stake was Dynavax Technologies: 2,500,000 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Technology and Real Estate.

On the sell side, the largest reduction was Quince Therapeutics, an estimated $1.31M trimmed.

  • Tang Capital Management's largest Q2 2024 buy was Dynavax Technologies: 2,500,000 shares worth $28.1M.
  • Tang Capital Management added most to ANI Pharmaceuticals in Q2 2024, an estimated $19.5M increase.
  • Tang Capital Management's biggest Q2 2024 reduction was Quince Therapeutics, cutting an estimated $1.31M.
  • Tang Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $24.5M.
  • Tang Capital Management's ten largest holdings make up 38% of its $982M portfolio in Q2 2024.
  • Tang Capital Management opened 43 new positions and closed 15 in Q2 2024.
  • Tang Capital Management's portfolio value rose 2.2% quarter-over-quarter to $982M.

Based on Tang Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.